A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study

被引：1

作者：

Giovannoni, Gavin ^{[1
]}

Boyko, Alexey ^{[2
]}

Correale, Jorge ^{[3
]}

Edan, Gilles ^{[4
]}

Freedman, Mark S. ^{[5
,6
]}

Montalban, Xavier ^{[7
]}

Rammohan, Kottil ^{[8
]}

Stefoski, Dusan ^{[9
]}

Yamout, Bassem ^{[10
,11
]}

Leist, Thomas

Aydemir, Aida ^{[12
]}

Borsi, Laszlo

di Cantogno, Elisabetta Verdun ^{[12
]}

机构：

[1] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England

[2] Pirogov Russian Natl Res Med Univ, Fed Ctr Brain Res & Neurotechnol, Dept Neurol Neurosurg & Med Genet, Moscow, Russia

[3] FLENI Inst, Dept Neurol, Buenos Aires, Argentina

[4] Univ Hosp Rennes, Dept Neurol, Rennes, France

[5] Univ Ottawa, Dept Med, Ottawa, ON, Canada

[6] Ottawa Hosp Res Inst, Ottawa, ON, Canada

[7] Hosp Univ Vall Hebron, Ctr Esclerosi Multiple Catalunya Cemcat, Dept Neurol Neuroimmunol, Barcelona, Spain

[8] Univ Miami, MS Res Ctr, Sch Med, Miami, FL USA

[9] Rush Med Coll, Dept Neurol Sci, Chicago, IL USA

[10] Harley St Med Ctr, Neurol Inst, Abu Dhabi, U Arab Emirates

[11] Amer Univ, Beirut Med Ctr, Beirut, Lebanon

[12] Merck KGaA, Darmstadt, Germany

来源：

NEURODEGENERATIVE DISEASE MANAGEMENT | 2023年 / 13卷 / 05期

关键词：

D O I：

10.2217/nmt-2023-0018

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

What is this summary about? Previous studies have shown that people living with multiple sclerosis ( MS) treated with cladribine tablets have fewer relapses (where new symptoms occur or existing symptoms get worse for 24 hours or more) and delayed disability progression (slowing down of the disease getting worse). The CLASSIC-MS study looked at the long-term effectiveness of treatment with cladribine tablets in people living with MS who had taken part in the original CLARITY and CLARITY Extension clinical studies. What were the results? Results showed that people treated with cladribine tablets maintained their mobility (the ability to move freely) for longer and experienced other positive effects long after their treatment ended, including being less likely to need further treatment for their MS. What do the results mean? The results obtained from CLASSIC-MS show that the benefits of taking cladribine tablets carry on even when patients stop taking the treatment.

引用

页码：261 / 268

页数：8

共 50 条

[41] Development and long-term safety evaluation of cladribine tablets as a short-course, oral therapy for relapsing and early forms of multiple sclerosis: ongoing clinical trials
Viglietta, V.
Miret, M.
Greenberg, S. J.
Mikol, D.
Weiner, J.
Alteri, E.
Chang, P.
Musch, B.
EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 235 - 235
[42] Development of cladribine tablets as a short-course, oral therapy for relapsing and early forms of multiple sclerosis: Ongoing clinical trials and long-term safety registry
Tomic, D.
Miret, M.
Greenberg, D.
Mikol, E.
Alteri, P.
Chang, B.
Musch
MULTIPLE SCLEROSIS, 2010, 16 (10): : 1283 - 1283
[43] The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets
Butzkueven, Helmut
Moore, Nicholas
Aydemir, Aida
Sonajalg, Jaak
Bezemer, Irene
Korhonen, Pasi
Sabido, Meritxell
CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (07) : 1167 - 1176
[44] A plain language summary of the long-term relugolix combination therapy study for uterine fibroids
Al-Hendy, Ayman
Lukes, Andrea S.
Venturella, Roberta
Villarroel, Claudio
McKain, Laura
Li, Yulan
Wagman, Rachel B.
Stewart, Elizabeth A.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (08)
[45] Long-term effect of fingolimod on cardiovascular functioning in people with relapsing-remitting multiple sclerosis
Haase, R.
Forberger, C.
Schilling, M.
Piatkowski, F.
Akgun, K.
Rudiger, H.
Ziemssen, T.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 609 - 610
[46] Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: A Plain Language Summary
Elliott, Perry
Drachman, Brian M.
Gottlieb, Stephen S.
Hoffman, James E.
Hummel, Scott L.
Lenihan, Daniel J.
Ebede, Ben
Gundapaneni, Balarama
Li, Benjamin
Sultan, Marla B.
Shah, Sanjiv J.
FUTURE CARDIOLOGY, 2023, 19 (01) : 7 - 17
[47] CLADCOMS- CLADribine tablets long-term Control Of MS - a post-marketing investigator driven study
Larsson, Veronica
Nilsson, Petra
Magdalena, Lucia Alonso
Svenningsson, Anders
Gunnarsson, Martin
Ayad, Ahmad
Vrethem, Magnus
Burman, Joachim
Lycke, Jan
Piehl, Fredrik
Fink, Katharina
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 968 - 969
[48] Treatment satisfaction in patients with highly-active relapsing multiple sclerosis treated with cladribine tablets: clarify-ms study interim analysis
Brochet, B.
Hupperts, R. H. Raymond
Langdon, D.
Solari, A.
Piehl, F.
Lechner-Scott, J.
Montalban, X.
Selmaj, K.
Valis, M.
Rejdak, K.
Havrdova, E. Kubala
Patti, F.
Alexandri, N.
Nolting, A.
Keller, B.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 623 - 623
[49] Treatment Satisfaction in Patients with Highly-active Relapsing Multiple Sclerosis Treated with Cladribine Tablets: CLARIFY-MS Study Interim Analysis
Brochet, Bruno
Hupperts, Raymond
Langdon, Dawn
Solari, Alessandra
Piehl, Fredrik
Lechner-Scott, Jeanette
Montalban, Xavier
Selmaj, Krzysztof
Valis, Martin
Havrdova, Eva
Rejdak, Konrad
Patti, Francesco
Alexandri, Nektaria
Nolting, Axel
Keller, Birgit
NEUROLOGY, 2021, 96 (15)
[50] Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods
Helen Bell Gorrod
Nicholas R. Latimer
Doris Damian
Robert Hettle
Gerard T. Harty
Schiffon L. Wong
Advances in Therapy, 2020, 37 : 225 - 239

← 1 2 3 4 5 →